Notably, Echevarría‐Vargas et al (2018) showed that the combination of BET/MEK inhibitors halted tumor growth of both BRAF/MAPK inhibitor‐resistant and immune therapy‐resistant melanoma cells in vivo and that this correlated with reduced levels of TCF19 protein (Fig 1B). The gene discussed is MAP2K7; the disease is melanoma.